HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study)

被引：0
作者：
Hasson, Hamid [1 ]
Galli, Laura [1 ]
Gallotta, Giulia [1 ]
Neri, Valentina [2 ]
Blanc, Pierluigi [3 ]
D'annunzio, Marco [4 ]
Morsica, Giulia [1 ]
Sollima, Salvatore [5 ]
Merli, Marco [1 ]
Lazzarin, Adriano [1 ,6 ]
Uberti-Foppa, Caterina [1 ]
机构：
[1] IRCCS Osped San Raffaele, Dept Infect Dis, I-20127 Milan, Italy
[2] L Spallanzani Natl Inst Infect Dis, Rome, Italy
[3] SS Annunziata Hosp, Dept Infect Dis, Florence, Italy
[4] Univ Bari, Inst Infect Dis, I-70121 Bari, Italy
[5] L Sacco Hosp Vialba, Dept Infect & Trop Dis, Milan, Italy
[6] Univ Vita Salute San Raffaele, Milan, Italy
来源：
NEW MICROBIOLOGICA | 2012年 / 35卷 / 04期
关键词：
HAART-simplification strategy; Anti-HCV drugs; LPV/r monotherapy; Tolerability of HIV/HCV treatments; LOPINAVIR-RITONAVIR MONOTHERAPY; MAINTENANCE THERAPY; 2; NUCLEOSIDES; HIV; ANTIRETROVIRALS; SUPPRESSION; MANAGEMENT;
D O I：
暂无
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The aim of this randomised, prospective, open-label, multicentre pilot clinical trial was to compare the 48-week toxicity profile of lopinavir/ritonavir (LPV/r) monotherapy with LPV/r-based HAART (KaMon = Kaletra monotherapy) in HIV/HCV patients undergoing HCV treatment. The study involved 30 HIV/HCV co-infected patients naive to anti-HCV therapy. One patient in each arm (6.7%) discontinued anti-HCV therapy because of adverse events. There were no significant between-group differences in terms of the proportion of patients experiencing AEs (p=0.999) or the number of grade 3-4 AEs (p=0.146). No HIV failure was observed. The safety profile of LPV/r monotherapy was similar to that of LPV/r-based HAART, thus encouraging HAART simplification in patients receiving anti-HCV treatment.
引用
收藏
页码：469 / 474
页数：6
相关论文
共 50 条
  • [21] Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients
    Inas E L-Khedr Mohamed
    Kadry Mohamed EL-Saeed
    Mahmoud Hassan Al-Sadik
    Christina Alphonse Anwar
    Egyptian Liver Journal, 11
  • [22] High interferon-stimulated gene ISG-15 expression affects HCV treatment outcome in patients co-infected with HIV and HCV
    Katsounas, Antonios
    Hubbard, Jonathan J.
    Wang, Crystal H.
    Zhang, Xiaozhen
    Dou, Diana
    Shivakumar, Bhavana
    Winter, Sophie
    Schlaak, Joerg F.
    Lempicki, Richard A.
    Masur, Henry
    Polis, Michael
    Kottilil, Shyam
    Osinusi, Anu
    JOURNAL OF MEDICAL VIROLOGY, 2013, 85 (06) : 959 - 963
  • [23] Peg-interferon and ribavirin treatment in HIV/HCV co-infected patients in Thailand: efficacy, safety and pharmacokinetics
    Smolders, E. J.
    Thammajaruk, N.
    de Kanter, C. T. M. M.
    Colbers, A.
    Chaiyahong, P.
    Cuprasitrut, T.
    Chittmittraprap, S.
    Apornpong, T.
    Khemnark, S.
    Tangkijvanich, P.
    Burger, D. M.
    Avihingsanon, A.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2018, 23 (03) : 295 - 305
  • [24] Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients
    Jain, M. K.
    Adams-Huet, B.
    Terekhova, D.
    Kushner, L. E.
    Bedimo, R.
    Li, X.
    Holodniy, M.
    JOURNAL OF VIRAL HEPATITIS, 2015, 22 (01) : 25 - 36
  • [25] Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France)
    Salmon-Ceron, Dominique
    Cohen, Julien
    Winnock, Maria
    Roux, Perrine
    Sadr, Firouze Bani
    Rosenthal, Eric
    Martin, Isabelle Poizot
    Loko, Marc-Arthur
    Mora, Marion
    Sogni, Philippe
    Spire, Bruno
    Dabis, Francois
    Carrieri, Maria Patrizia
    BMC HEALTH SERVICES RESEARCH, 2012, 12
  • [26] Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France)
    Dominique Salmon-Ceron
    Julien Cohen
    Maria Winnock
    Perrine Roux
    Firouze Bani Sadr
    Eric Rosenthal
    Isabelle Poizot Martin
    Marc-Arthur Loko
    Marion Mora
    Philippe Sogni
    Bruno Spire
    François Dabis
    Maria Patrizia Carrieri
    BMC Health Services Research, 12
  • [27] Sustained Long-Term Decline in Anti-HCV Neutralizing Antibodies in HIV/HCV-Coinfected Patients Five Years after HCV Therapy: A Retrospective Study
    Sepulveda-Crespo, Daniel
    Volpi, Camilla
    Amigot-Sanchez, Rafael
    Yelamos, Maria Belen
    Diez, Cristina
    Gomez, Julian
    Hontanon, Victor
    Berenguer, Juan
    Gonzalez-Garcia, Juan
    Martin-Escolano, Ruben
    Resino, Salvador
    Martinez, Isidoro
    PHARMACEUTICALS, 2024, 17 (09)
  • [28] Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients
    Vachon, Marie-Louise C.
    Factor, Stephanie H.
    Branch, Andrea D.
    Fiel, Maria-Isabel
    Rodriguez-Torres, Maribel
    Braeu, Norbert
    Sterling, Richard K.
    Slim, Jihad
    Talal, Andrew H.
    Dieterich, Douglas T.
    Sulkowski, Mark S.
    JOURNAL OF HEPATOLOGY, 2011, 54 (01) : 41 - 47
  • [29] Epidemiological characteristics and real-world treatment outcomes of hepatitis C among HIV/HCV co-infected patients in Myanmar: A prospective cohort study
    Swe, Thein Min
    Johnson, Derek. C.
    Mar, Htay Thet
    Thit, Phone
    Homan, Tobias
    Chu, Cherry May
    Mon, Phyu Ei
    Thwe, Thin Thin
    Soe, Kyi Pyar
    Ei, Win Le Shwe Sin
    Tun, Nyan Lynn
    Lwin, Kyaw Zay
    Karakozian, Hayk
    Aung, Khin Sanda
    Nguyen, Aude
    Ciglenecki, Iza
    Tamayo, Natalia
    Loarec, Anne
    HEALTH SCIENCE REPORTS, 2023, 6 (02)
  • [30] The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study
    Chin-Hui Yang
    Kuan-Jung Chen
    Jih-Jin Tsai
    Yu-Hui Lin
    Shu-Hsing Cheng
    Kwei-Feng Wang
    Hung-Yi Chiou
    BMC Infectious Diseases, 14
12345